Pancreatic cancer has long been one of the most lethal diagnoses in medicine, largely because it spreads early and hides from ...

Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced that its pancreatic cancer project will receive public funding from the Investitions- und ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its ...

Niigata, Japan – The research group of Professor Kamimura in Niigata University have established a novel pancreatic carcinogenesis model in wild-type rats utilizing the pancreas-targeted selective ...

Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...

An international team of researchers led by Max Delbrück Center Scientific Director Professor Maike Sander, MD, has for the first time developed an organoid model of human pluripotent stem ...

Pancreatic cancer has a significantly poor prognosis; therefore, the development of effective treatments is an unmet clinical need. The major drawback in this field was the lack of useful model ...